Integrating epidemiology and genomics data to estimate the prevalence of acquired cysteine drug targets in the U.S. cancer patient population [0.03%]
整合流行病学和基因组学数据以估计在美国癌症患者人群中获得的胱氨酸药物靶点的流行率
Adith S Arun,David Liarakos,Gaurav Mendiratta et al.
Adith S Arun et al.
Reliable estimates for the number of cancer patients with a specific mutation can help quantify the size of the population that could potentially benefit from a targeted therapy. We adapt our previously developed approach for estimating gen...
CYP3A5 and POR gene polymorphisms as predictors of infection and graft rejection in post-liver transplant patients treated with tacrolimus - a cohort study [0.03%]
CYP3A5和POR基因多态性作为预测接受他克莫司治疗的肝移植患者感染和移植物排斥的指标-队列研究
Graziella D&#x; Agostino Ribeiro Naldi,Ariane Boccoli Minari,Thales D M Pereira et al.
Graziella D&#x; Agostino Ribeiro Naldi et al.
Liver transplantation is the only curative option for patients with advanced stages of liver disease, with tacrolimus used as the immunosuppressive drug of choice. Genetic variability can interfere with drug response, potentially leading to...
Genetic markers of early response to lurasidone in acute schizophrenia [0.03%]
急性精神分裂症患者对鲁拉西酮早期反应的遗传标记物
Akane Yoshikawa,Jiang Li,Ney Alliey-Rodriguez et al.
Akane Yoshikawa et al.
Prediction of treatment response by genetic biomarkers has potential for clinical use and contributes to the understanding of pathophysiology and drug mechanism of action. The purpose of this study is to detect genetic biomarkers possibly a...
Randomized Controlled Trial
The pharmacogenomics journal. 2025 Feb 20;25(2):3. DOI:10.1038/s41397-024-00360-z 2025
Systematic identification of cancer pathways and potential drugs for intervention through multi-omics analysis [0.03%]
通过多组学分析系统识别癌症通路及潜在的干预药物
Tuan Xu,Deborah K Ngan,Wei Zheng et al.
Tuan Xu et al.
The pathogenesis of cancer is complicated, and different types of cancer often exhibit different gene mutations resulting in different omics profiles. The purpose of this study was to systematically identify cancer-specific biological pathw...
The association between the number of HLA risk alleles and drug allergy and its implications for HLA screening - a case-control study [0.03%]
HLA风险等位基因的数量与药物过敏的关联及其对HLA筛查的影响-一项病例对照研究
Lisanne E N Manson,Jacqueline D H Anholts,Jos J M Drabbels et al.
Lisanne E N Manson et al.
Patients carrying specific HLA risk alleles are at higher risk for developing drug hypersensitivity reactions, yet pre-therapeutic screening is uncommon. We examined whether patients with a history of drug allergies have more HLA risk allel...
Genetic association analysis and frequency of NUDT15*3 with thiopurine-induced myelosuppression in patients with inflammatory bowel disease in a large Dutch cohort [0.03%]
荷兰大样本炎症性肠病患者硫嘌呤诱导的骨髓抑制的遗传关联分析及NUDT15*3等位基因频率研究
Maarten J Deenen,Anouk J van Noordenburg,Joëlle Bouwens-Bijsterveld et al.
Maarten J Deenen et al.
Thiopurine drugs are cornerstone treatment for patients with inflammatory bowel disease (IBD). The most common adverse drug reaction is thiopurine-induced myelosuppression (TIM), that may partly be explained by the genetic polymorphism NUDT...
Polygenic score analyses on antidepressant response in late-life depression, results from the IRL-GRey study [0.03%]
基于IRL-GREY研究的老年抑郁患者抗抑郁药物反应的多基因得分分析
Samar S M Elsheikh,Victoria S Marshe,Xiaoyu Men et al.
Samar S M Elsheikh et al.
Late-life depression (LLD) is often accompanied by medical comorbidities such as psychiatric disorders and cardiovascular diseases, posing challenges to antidepressant treatment. Recent studies highlighted significant associations between t...
Plasma concentrations of venetoclax and Pharmacogenetics correlated with drug efficacy in treatment naive leukemia patients: a retrospective study [0.03%]
维奈克拉血药浓度和药物基因组学与初治白血病患者疗效的相关性研究
Yue Li,Qing Wan,Jiaqi Wan et al.
Yue Li et al.
Venetoclax (VEN) was the only Bcl-2 inhibitor approved yet and showed large differences in clinical efficacy. The aim of the study was to explore the relationships between the plasma concentration and efficacy of VEN, and identify potential...
Implementation of pharmacogenetic testing in pediatric oncology: barriers and facilitators assessment at eight Canadian academic health centres [0.03%]
加拿大八所学术医疗中心实施儿童肿瘤药物基因组检测：障碍与促进因素评估
Jeanette Cooper,Joshua Pratt,Jamie Park et al.
Jeanette Cooper et al.
Pharmacogenetic (PGx) testing can enhance drug safety, improve efficacy, and reduce the risk of toxicity. However, the implementation of PGx testing in Canadian pediatric oncology centers has been limited. To address this gap, the aim of th...
Multicenter Study
The pharmacogenomics journal. 2024 Nov 19;24(6):36. DOI:10.1038/s41397-024-00356-9 2024
Correction to: A pharmacogenomic study on the pharmacokinetics of tacrolimus in healthy subjects using the DMETTM Plus platform [0.03%]
Correction to: 采用DMETTM Plus平台对健康受试者他克莫司药代动力学的药物基因组学研究
Y Choi,F Jiang,H An et al.
Y Choi et al.
Published Erratum
The pharmacogenomics journal. 2024 Nov 18;24(6):35. DOI:10.1038/s41397-024-00354-x 2024